Lead Sponsor

Hospices Civils de Lyon

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Lung cancer (n= 30):
•Adult patients
•Patients who gave its written informed consent to participate to the study
•Weight at inclusion ≥ 48 kg
•NSCLC histology only
•Stage IV according to 8th TNM classification
•Planned to be treated with immunotherapy (+/- chemotherapy) as a first line treatment in metastatic setting
•PD-L1 status on primary tumor available at the inclusion
•Patients affiliated to a social insurance regime
•Head and neck cancer (n= 30):
•Adult patients
•Patients who gave its written informed consent to participate to the study
•Weight at inclusion ≥ 48 kg
•Recurrent or metastatic epidermoid carcinomas from oral cavity, oropharynx, hypopharynx, larynx (except nasopharynx)
•Stage IV according to 8th TNM classification
•Planned to be treated with immunotherapy (+/- chemotherapy)
•PD-L1 status on primary tumor available at the inclusion
•Patients affiliated to a social insurance regime

•History of previous cancers, except for adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, treated and with no evidence of disease for ≥ 5 years
•Patients under tutorship or guardianship
•Pregnant or breast feeding women
•Patients under psychiatric care
•\- Patients already treated with immunotherapy

Related studies

NCT07363811 · Metastatic NSCLC - Non-Small Cell Lung Cancer

NCT07050043 · NSCLC (Non-small Cell Lung Carcinoma), First Line Therapy, and more

NCT04303780 · KRAS p, G12c Mutated /Advanced Metastatic NSCLC

NCT05980000 · Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, and more

NCT05403385 · Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer

Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers